LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 173

Search options

  1. Article ; Online: Emerging drugs for immune thrombocytopenia (ITP).

    Salama, Abdulgabar

    Expert opinion on emerging drugs

    2017  Volume 22, Issue 1, Page(s) 27–38

    Abstract: Introduction: Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by autoantibody production against platelets, increased platelet destruction, and, in some cases, impaired thrombopoiesis. The majority of affected patients have ... ...

    Abstract Introduction: Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by autoantibody production against platelets, increased platelet destruction, and, in some cases, impaired thrombopoiesis. The majority of affected patients have significant bleeding risks due to low platelet counts and require treatment. The etiology of ITP is an immunological labyrinth. Currently available treatment options are usually not only nonspecific, but are also associated with some risks. Areas covered: Several useful drugs for the treatment of ITP are currently available. Furthermore, ongoing trials with new drugs and preclinical development of additional drugs may help to improve and determine their value. Expert opinion: ITP is a heterogeneous complex requiring individualized treatment. None of the available drugs are specific, nor are they invariably safe and effective. Thus, the need for specific therapy is evident.
    MeSH term(s) Animals ; Autoantibodies/immunology ; Blood Platelets/immunology ; Drug Design ; Humans ; Purpura, Thrombocytopenic, Idiopathic/drug therapy ; Purpura, Thrombocytopenic, Idiopathic/physiopathology ; Thrombopoiesis/immunology
    Chemical Substances Autoantibodies
    Language English
    Publishing date 2017-03
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2061369-6
    ISSN 1744-7623 ; 1472-8214
    ISSN (online) 1744-7623
    ISSN 1472-8214
    DOI 10.1080/14728214.2017.1294158
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Se 1925: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Book ; Conference proceedings: Therapie mit Immunglobulinen und deren Derivaten

    Salama, Abdulgabar

    (Infektionen und Autoimmunerkrankungen ; 2)

    1993  

    Institution Behringwerke
    Event/congress Internationales Immunologie-Symposium (2, 1992, FrankfurtMain)
    Author's details Internationales Behring Immunologie-Symposium, 12. - 14. November 1992, Frankfurt am Main. A. Salama ... (Hrsg.)
    Series title Infektionen und Autoimmunerkrankungen ; 2
    Collection
    Keywords Autoimmune Diseases / drug therapy / congresses ; Mycoses / drug therapy / congresses ; Bacterial Infections / drug therapy / congresses ; IgG / therapeutic use / congresses ; Infektionskrankheit ; Autoaggressionskrankheit
    Subject Ansteckende Krankheit ; Kontagiöse Krankheit ; Infektionskrankheiten ; Autoantikörperkrankheit ; Autoimmunkrankheit ; Autoimmunopathie ; Autoimmunerkrankung
    Language German
    Size VII, 311 S. : Ill., graph. Darst.
    Publisher Univ.-Verl. Jena
    Publishing place Jena
    Document type Book ; Conference proceedings
    HBZ-ID HT005044151
    ISBN 3-86007-063-0 ; 978-3-86007-063-5
    Database Catalogue ZB MED Medicine, Health

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    1993 A 3823 order for loan Magazin

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Autoimmune Thrombocytopenia Complicated by EDTA- and/or Citrate-Dependent Pseudothrombocytopenia.

    Salama, Abdulgabar

    Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

    2015  Volume 42, Issue 5, Page(s) 345–348

    Abstract: Background: Pseudothrombocytopenia (PTCP) is a well-known phenomenon. However, confusion may occur due to unusual characteristics.: Case reports: Two patients with autoimmune thrombocytopenia (ITP) and long-lasting PTCP are described. Initially, only ...

    Abstract Background: Pseudothrombocytopenia (PTCP) is a well-known phenomenon. However, confusion may occur due to unusual characteristics.
    Case reports: Two patients with autoimmune thrombocytopenia (ITP) and long-lasting PTCP are described. Initially, only the diagnosis of ITP was confirmed. During observation, discrepancies were recognized between clinical findings and platelet counts. Re-examination resulted in the additional diagnosis of EDTA-dependent PTCP. Subsequently, the latter diagnosis was changed to citrate-dependent PTCP in both cases. Interestingly, PTCP was observed to change again and became recognizable in citrate or heparin, and only during the first 20-30 min following phlebotomy in EDTA specimens.
    Conclusion: The incidence of concomitant ITP with PTCP might be higher than previously reported, and PTCP may have variable dynamics and characteristics.
    Language English
    Publishing date 2015-08-04
    Publishing country Switzerland
    Document type Case Reports
    ZDB-ID 2100848-6
    ISSN 1660-3818 ; 1660-3796
    ISSN (online) 1660-3818
    ISSN 1660-3796
    DOI 10.1159/000437220
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 959: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Clinically and/or Serologically Misleading Findings Surrounding Immune Haemolytic Anaemias.

    Salama, Abdulgabar

    Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

    2015  Volume 42, Issue 5, Page(s) 311–315

    Abstract: Autoimmune haemolytic anaemias (AIHAs) are well-characterized disorders. They can be differentiated from one another and from other non-immune haemolytic anaemias by clinical, laboratory and serological testing. However, several misleading clinical ... ...

    Abstract Autoimmune haemolytic anaemias (AIHAs) are well-characterized disorders. They can be differentiated from one another and from other non-immune haemolytic anaemias by clinical, laboratory and serological testing. However, several misleading clinical presentations and/or serological findings may result in misinterpretation, delay and/or misdiagnosis. Such failures are avoidable by adequate clinical and serological experience of the responsible physicians and serologists or, at least, by an optimised bidirectional communication. As long as this has not been achieved, unpleasant failures are to be expected. A true diagnosis of AIHA can neither be verified by clinical nor serological findings alone. Thus, a collective clinical and serological picture remains obligatory for fulfilling the criteria of optimal diagnosis and therapy. Ultimately, the majority of pioneer scientific and practical work in this field stems from scientists who were simultaneously involved in both the clinic and serology.
    Language English
    Publishing date 2015-08-10
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2100848-6
    ISSN 1660-3818 ; 1660-3796
    ISSN (online) 1660-3818
    ISSN 1660-3796
    DOI 10.1159/000438960
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 959: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Treatment Options for Primary Autoimmune Hemolytic Anemia: A Short Comprehensive Review.

    Salama, Abdulgabar

    Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie

    2015  Volume 42, Issue 5, Page(s) 294–301

    Abstract: Until now, treatment of primary autoimmune hemolytic anemia of the warm type (wAIHA) is primarily based on immunosuppression. However, many patients do not respond adequately to treatment, and treated patients may develop severe side effects due to ... ...

    Abstract Until now, treatment of primary autoimmune hemolytic anemia of the warm type (wAIHA) is primarily based on immunosuppression. However, many patients do not respond adequately to treatment, and treated patients may develop severe side effects due to uncontrolled, mixed and/or long-lasting immunosuppression. Unfortunately, the newly used therapeutic monoclonal antibodies are unspecific and remain frequently ineffective. Thus, development of a specific therapy for AIHA is necessary. The ideal therapy would be the identification and elimination of the causative origin of autoimmunization and/or the correction or reprogramming of the dysregulated immune components. Blood transfusion is the most rapidly effective measure for patients who develop or may develop hypoxic anemia. Although some effort has been made to guide physicians on how to adequately treat patients with AIHA, a number of individual aspects should be considered prior to treatment. Based on my serological and clinical experience and the analysis of evidence-based studies, we remain far from any optimized therapeutic measures for all AIHA patients. Today, the old standard therapy using controlled steroid administration, with or without azathioprine or cyclophosphamide, is, when complemented with erythropoiesis-stimulating agents, still the most effective therapy in wAIHA. Rituximab or other monoclonal antibodies may be used instead of splenectomy in therapy-refractory patients.
    Language English
    Publishing date 2015-08-10
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2100848-6
    ISSN 1660-3818 ; 1660-3796
    ISSN (online) 1660-3818
    ISSN 1660-3796
    DOI 10.1159/000438731
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 959: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Autoimmunhämolytische Anämien: Diagnose und Therapie

    Salama, Abdulgabar

    Transfusionsmedizin - Immunhämatologie, Hämotherapie, Immungenetik, Zelltherapie

    2017  Volume 7, Issue 02, Page(s) 104–119

    Language German
    Publishing date 2017-05-01
    Publisher Georg Thieme Verlag KG
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 2599278-8
    ISSN 2191-8813 ; 2191-8805
    ISSN (online) 2191-8813
    ISSN 2191-8805
    DOI 10.1055/s-0043-102720
    Database Thieme publisher's database

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6977: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Treatment Options for Primary Autoimmune Hemolytic Anemia: A Short Comprehensive Review

    Salama, Abdulgabar

    Transfusion Medicine and Hemotherapy

    2015  Volume 42, Issue 5, Page(s) 294–301

    Abstract: Until now, treatment of primary autoimmune hemolytic anemia of the warm type (wAIHA) is primarily based on immunosuppression. However, many patients do not respond adequately to treatment, and treated patients may develop severe side effects due to ... ...

    Institution Institute for Transfusion Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany
    Abstract Until now, treatment of primary autoimmune hemolytic anemia of the warm type (wAIHA) is primarily based on immunosuppression. However, many patients do not respond adequately to treatment, and treated patients may develop severe side effects due to uncontrolled, mixed and/or long-lasting immunosuppression. Unfortunately, the newly used therapeutic monoclonal antibodies are unspecific and remain frequently ineffective. Thus, development of a specific therapy for AIHA is necessary. The ideal therapy would be the identification and elimination of the causative origin of autoimmunization and/or the correction or reprogramming of the dysregulated immune components. Blood transfusion is the most rapidly effective measure for patients who develop or may develop hypoxic anemia. Although some effort has been made to guide physicians on how to adequately treat patients with AIHA, a number of individual aspects should be considered prior to treatment. Based on my serological and clinical experience and the analysis of evidence-based studies, we remain far from any optimized therapeutic measures for all AIHA patients. Today, the old standard therapy using controlled steroid administration, with or without azathioprine or cyclophosphamide, is, when complemented with erythropoiesis-stimulating agents, still the most effective therapy in wAIHA. Rituximab or other monoclonal antibodies may be used instead of splenectomy in therapy-refractory patients.
    Keywords Autoimmune hemolysis ; AIHA ; Azathioprine ; Blood transfusion ; Corticosteroids ; Cyclophosphamide ; Cushingߣs syndrome ; Erythropoietin ; Intravenous IgG ; Mycophenolate ; Rituximab ; Splenectomy
    Language English
    Publishing date 2015-08-10
    Publisher S. Karger GmbH
    Publishing place Freiburg, Germany
    Document type Article
    Note Review Article
    ZDB-ID 2100848-6
    ISSN 1660-3818 ; 1660-3796
    ISSN (online) 1660-3818
    ISSN 1660-3796
    DOI 10.1159/000438731
    Database Karger publisher's database

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 959: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: Clinically and/or Serologically Misleading Findings Surrounding Immune Haemolytic Anaemias

    Salama, Abdulgabar

    Transfusion Medicine and Hemotherapy

    2015  Volume 42, Issue 5, Page(s) 311–315

    Abstract: Autoimmune haemolytic anaemias (AIHAs) are well-characterized disorders. They can be differentiated from one another and from other non-immune haemolytic anaemias by clinical, laboratory and serological testing. However, several misleading clinical ... ...

    Institution Institute for Transfusion Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany
    Abstract Autoimmune haemolytic anaemias (AIHAs) are well-characterized disorders. They can be differentiated from one another and from other non-immune haemolytic anaemias by clinical, laboratory and serological testing. However, several misleading clinical presentations and/or serological findings may result in misinterpretation, delay and/or misdiagnosis. Such failures are avoidable by adequate clinical and serological experience of the responsible physicians and serologists or, at least, by an optimised bidirectional communication. As long as this has not been achieved, unpleasant failures are to be expected. A true diagnosis of AIHA can neither be verified by clinical nor serological findings alone. Thus, a collective clinical and serological picture remains obligatory for fulfilling the criteria of optimal diagnosis and therapy. Ultimately, the majority of pioneer scientific and practical work in this field stems from scientists who were simultaneously involved in both the clinic and serology.
    Keywords Coombs-negative ; Agglutination ; Immune haemolysis ; Autoimmune haemolytic anaemia ; AIHA ; Positive DAT ; Negative DAT ; C ; d DAT ; IgG DAT
    Language English
    Publishing date 2015-08-10
    Publisher S. Karger GmbH
    Publishing place Freiburg, Germany
    Document type Article
    Note Review Article
    ZDB-ID 2100848-6
    ISSN 1660-3818 ; 1660-3796
    ISSN (online) 1660-3818
    ISSN 1660-3796
    DOI 10.1159/000438960
    Database Karger publisher's database

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 959: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Autoimmune Thrombocytopenia Complicated by EDTA- and/or Citrate-Dependent Pseudothrombocytopenia

    Salama, Abdulgabar

    Transfusion Medicine and Hemotherapy

    2015  Volume 42, Issue 5, Page(s) 345–348

    Abstract: Background: Pseudothrombocytopenia (PTCP) is a well-known phenomenon. However, confusion may occur due to unusual characteristics. Case Reports: Two patients with autoimmune thrombocytopenia (ITP) and long-lasting PTCP are described. Initially, only the ... ...

    Institution Institute for Transfusion Medicine, Charité - Universitätsmedizin Berlin, Berlin, Germany
    Abstract Background: Pseudothrombocytopenia (PTCP) is a well-known phenomenon. However, confusion may occur due to unusual characteristics. Case Reports: Two patients with autoimmune thrombocytopenia (ITP) and long-lasting PTCP are described. Initially, only the diagnosis of ITP was confirmed. During observation, discrepancies were recognized between clinical findings and platelet counts. Re-examination resulted in the additional diagnosis of EDTA-dependent PTCP. Subsequently, the latter diagnosis was changed to citrate-dependent PTCP in both cases. Interestingly, PTCP was observed to change again and became recognizable in citrate or heparin, and only during the first 20-30 min following phlebotomy in EDTA specimens. Conclusion: The incidence of concomitant ITP with PTCP might be higher than previously reported, and PTCP may have variable dynamics and characteristics.
    Keywords Pseudothrombocytopenia ; ITP ; EDTA-dependent ; Citrate-dependent ; Heparin-dependent
    Language English
    Publishing date 2015-08-04
    Publisher S. Karger GmbH
    Publishing place Freiburg, Germany
    Document type Article
    Note Case Report
    ZDB-ID 2100848-6
    ISSN 1660-3818 ; 1660-3796
    ISSN (online) 1660-3818
    ISSN 1660-3796
    DOI 10.1159/000437220
    Database Karger publisher's database

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 959: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Current treatment options for primary immune thrombocytopenia.

    Salama, Abdulgabar

    Expert review of hematology

    2011  Volume 4, Issue 1, Page(s) 107–118

    Abstract: Traditional treatment of primary (idiopathic) immune thrombocytopenia (ITP) predominantly consists of immune suppression and/or modulation. In addition, many treated patients develop severe adverse effects, and approximately a third of patients do not ... ...

    Abstract Traditional treatment of primary (idiopathic) immune thrombocytopenia (ITP) predominantly consists of immune suppression and/or modulation. In addition, many treated patients develop severe adverse effects, and approximately a third of patients do not respond. Two of the newly developed thrombopoietin-receptor agonists, romiplostim and eltrombopag, are now available for the treatment of ITP. Both drugs have been shown to increase the production of platelets in a dose-dependent manner, and to compensate, at least partly, for thrombocytopenia in the majority of ITP patients. The reported adverse effects are predominantly mild, although serious and long-term side effects cannot be excluded. Nevertheless, these drugs are increasingly used in the treatment of patients with thrombocytopenias. Thrombopoietin-receptor agonists do not appear to stop either the production of autoantibodies or the accelerated platelet destruction observed in ITP. Thus, the need for a specific therapy is essential, and the ultimate solution is to clarify and halt the mechanism(s) that lead to the development of ITP.
    MeSH term(s) Antibodies, Monoclonal, Murine-Derived/therapeutic use ; Antineoplastic Agents/therapeutic use ; Azathioprine/therapeutic use ; Benzoates/therapeutic use ; Humans ; Hydrazines/therapeutic use ; Immunoglobulins, Intravenous/therapeutic use ; Isoantibodies/immunology ; Isoantibodies/therapeutic use ; Pyrazoles/therapeutic use ; Receptors, Fc/therapeutic use ; Receptors, Thrombopoietin/agonists ; Receptors, Thrombopoietin/metabolism ; Recombinant Fusion Proteins/therapeutic use ; Rho(D) Immune Globulin ; Rituximab ; Thrombocytopenia/drug therapy ; Thrombopoietin/therapeutic use
    Chemical Substances Antibodies, Monoclonal, Murine-Derived ; Antineoplastic Agents ; Benzoates ; Hydrazines ; Immunoglobulins, Intravenous ; Isoantibodies ; Pyrazoles ; RHO(D) antibody ; Receptors, Fc ; Receptors, Thrombopoietin ; Recombinant Fusion Proteins ; Rho(D) Immune Globulin ; Rituximab (4F4X42SYQ6) ; Thrombopoietin (9014-42-0) ; romiplostim (GN5XU2DXKV) ; Azathioprine (MRK240IY2L) ; eltrombopag (S56D65XJ9G)
    Language English
    Publishing date 2011-02
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2516804-6
    ISSN 1747-4094 ; 1747-4086
    ISSN (online) 1747-4094
    ISSN 1747-4086
    DOI 10.1586/ehm.10.76
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6943: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top